Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer

Abstract Fibroblast growth factor receptor 2 (FGFR2) has two isoforms: IIIb type and IIIc type. Clinicopathologic significance of these two FGFR2 subtypes in gastric cancer remains to be known. This study aimed to clarify the clinicopathologic difference of FGFR2IIIb and/or FGFR2IIIc overexpression....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masakazu Yashiro, Kenji Kuroda, Go Masuda, Tomohisa Okuno, Yuichiro Miki, Yurie Yamamoto, Tomohiro Sera, Atsushi Sugimoto, Shuhei Kushiyama, Sadaaki Nishimura, Shingo Togano, Masaichi Ohira
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/57f653c36cdc4e4f86e8dfd190fdd59e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57f653c36cdc4e4f86e8dfd190fdd59e
record_format	dspace
spelling	oai:doaj.org-article:57f653c36cdc4e4f86e8dfd190fdd59e2021-12-02T13:20:12ZClinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer10.1038/s41598-021-84107-x2045-2322https://doaj.org/article/57f653c36cdc4e4f86e8dfd190fdd59e2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84107-xhttps://doaj.org/toc/2045-2322Abstract Fibroblast growth factor receptor 2 (FGFR2) has two isoforms: IIIb type and IIIc type. Clinicopathologic significance of these two FGFR2 subtypes in gastric cancer remains to be known. This study aimed to clarify the clinicopathologic difference of FGFR2IIIb and/or FGFR2IIIc overexpression. A total of 562 patients who underwent gastrectomy was enrolled. The expressions of FGFR2IIIb and FGFR2IIIc were retrospectively examined by immunohistochemistry or fluorescence in situ hybridization (FISH) using the 562 gastric tumors. We evaluated the correlation between clinicopathologic features and FGFR2IIIb overexpression and/or FGFR2IIIc overexpression in gastric cancer. FGFR2IIIb overexpression was observed in 28 cases (4.9%), and FGFR2IIIc overexpression was observed in four cases (0.7%). All four FGFR2IIIc cases were also positive for FGFR2IIIb, but not in the same cancer cells. FGFR2IIIb and/or FGFR2IIIc overexpression was significantly correlated with lymph node metastasis and clinical stage. Both FGFR2IIIb and FGFR2IIIc were significantly associated with poor overall survival. A multivariate analysis showed that FGFR2IIIc expression was significantly correlated with overall survival. FISH analysis indicated that FGFR2 amplification was correlated with FGFR2IIIb and/or FGFR2IIIc overexpression. These findings suggested that gastric tumor overexpressed FGFR2IIIc and/or FGFR2IIIb at the frequency of 4.9%. FGFR2IIIc overexpression might be independent prognostic factor for patients with gastric cancer.Masakazu YashiroKenji KurodaGo MasudaTomohisa OkunoYuichiro MikiYurie YamamotoTomohiro SeraAtsushi SugimotoShuhei KushiyamaSadaaki NishimuraShingo ToganoMasaichi OhiraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Masakazu Yashiro Kenji Kuroda Go Masuda Tomohisa Okuno Yuichiro Miki Yurie Yamamoto Tomohiro Sera Atsushi Sugimoto Shuhei Kushiyama Sadaaki Nishimura Shingo Togano Masaichi Ohira Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer
description	Abstract Fibroblast growth factor receptor 2 (FGFR2) has two isoforms: IIIb type and IIIc type. Clinicopathologic significance of these two FGFR2 subtypes in gastric cancer remains to be known. This study aimed to clarify the clinicopathologic difference of FGFR2IIIb and/or FGFR2IIIc overexpression. A total of 562 patients who underwent gastrectomy was enrolled. The expressions of FGFR2IIIb and FGFR2IIIc were retrospectively examined by immunohistochemistry or fluorescence in situ hybridization (FISH) using the 562 gastric tumors. We evaluated the correlation between clinicopathologic features and FGFR2IIIb overexpression and/or FGFR2IIIc overexpression in gastric cancer. FGFR2IIIb overexpression was observed in 28 cases (4.9%), and FGFR2IIIc overexpression was observed in four cases (0.7%). All four FGFR2IIIc cases were also positive for FGFR2IIIb, but not in the same cancer cells. FGFR2IIIb and/or FGFR2IIIc overexpression was significantly correlated with lymph node metastasis and clinical stage. Both FGFR2IIIb and FGFR2IIIc were significantly associated with poor overall survival. A multivariate analysis showed that FGFR2IIIc expression was significantly correlated with overall survival. FISH analysis indicated that FGFR2 amplification was correlated with FGFR2IIIb and/or FGFR2IIIc overexpression. These findings suggested that gastric tumor overexpressed FGFR2IIIc and/or FGFR2IIIb at the frequency of 4.9%. FGFR2IIIc overexpression might be independent prognostic factor for patients with gastric cancer.
format	article
author	Masakazu Yashiro Kenji Kuroda Go Masuda Tomohisa Okuno Yuichiro Miki Yurie Yamamoto Tomohiro Sera Atsushi Sugimoto Shuhei Kushiyama Sadaaki Nishimura Shingo Togano Masaichi Ohira
author_facet	Masakazu Yashiro Kenji Kuroda Go Masuda Tomohisa Okuno Yuichiro Miki Yurie Yamamoto Tomohiro Sera Atsushi Sugimoto Shuhei Kushiyama Sadaaki Nishimura Shingo Togano Masaichi Ohira
author_sort	Masakazu Yashiro
title	Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer
title_short	Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer
title_full	Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer
title_fullStr	Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer
title_full_unstemmed	Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer
title_sort	clinical difference between fibroblast growth factor receptor 2 subclass, type iiib and type iiic, in gastric cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/57f653c36cdc4e4f86e8dfd190fdd59e
work_keys_str_mv	AT masakazuyashiro clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT kenjikuroda clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT gomasuda clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT tomohisaokuno clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT yuichiromiki clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT yurieyamamoto clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT tomohirosera clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT atsushisugimoto clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT shuheikushiyama clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT sadaakinishimura clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT shingotogano clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer AT masaichiohira clinicaldifferencebetweenfibroblastgrowthfactorreceptor2subclasstypeiiibandtypeiiicingastriccancer
_version_	1718393212068954112

Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer

Ejemplares similares